News Denali slides after ALS drug flunks clinical test Another clinical trial setback disappoints the ALS patient community, this time involving Denali's eIF2B agonist DNL343.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
